Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...
Avoid co-administration of XOLREMDI and strong CYP3A4 inducers. Reduce XOLREMDI daily dosage when administered with strong CYP3A4 inhibitors. Monitor more frequently for adverse reactions associated ...
Rigel Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamatinib, the company's oral ...
5-hydroxyomeprazole is then transformed into 5-hydroxyomeprazole sulfone by CYP3A4. Omeprazole is metabolized directly in part by CYP3A4 to omeprazole sulfone, then transformed into 5 ...